Inhibition of COX-2 by celecoxib resulted in loss of intra-tumor PGE2 levels and reduced tumor growth with increased apoptosis of both tumor and stromal cells (inflammatory and neovascular) in head and neck xenograft tumors (27). This evidence concerns the gene PTGS2 and neoplasm.